nach oben

Cancer Causes & Control

Erschienen in:

01.10.2007 | Original Paper

Declines in breast cancer after the WHI: apparent impact of hormone therapy

verfasst von: Christina A. Clarke, Sally L. Glaser

Erschienen in: Cancer Causes & Control | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

Large numbers of US women stopped taking hormone therapies (HT), especially estrogen/progestin (EP) formulations, after the Women’s Health Initiative trial detected elevated risks of breast cancer in EP users and was halted in July 2002. Recent reports have indicated substantial and significant declines in population-based breast cancer incidence, particularly hormone-sensitive forms, for 2003 and 2004. Are these events linked? This commentary considers the available evidence linking the mass cessation of HT in 2002 to the breast cancer incidence declines of 2003/2004 and quantifies the potential impact of the cessation on the overall burden of breast cancer in the US.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. Jama 288(3):321–333PubMedCrossRef

Colditz GA (2005) Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 11(2 Pt 2):909s–917sPubMed

Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321(5):293–297PubMedCrossRef

Kolata G, Peterson M (2002) Hormone replacement study a shock to the medical system. New York Times 2002 July 10

Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. Jama 291(1):47–53PubMedCrossRef

Ravdin PM, Cronin KA, Howlader N, Chlebowski RT, Berry DA (2006) A sharp decrease in breast cancer incidence in the United States in 2003. Breast Cancer Res Treat 100(Suppl 1):S6

Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, Jemal A et al (2006) Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among US Hispanic/Latino populations. Cancer 107(8):1711–1742PubMedCrossRef

Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ (2006) Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 24(33):e49–e50PubMedCrossRef

Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356(16):1670–1674PubMedCrossRef

10.

Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K (2004) Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140(3):184–188PubMed

11.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama 280(7):605–613PubMedCrossRef

12.

Katalinic A, Rawal R (2007) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. E-published on 24 April 2007

13.

Robbins AS, Clarke CA (2007) Regional changes in hormone therapy use and breast cancer incidence, California, 2001–2004. J Clinic Oncol (in press)

14.

Wysowski DK, Governale LA (2005) Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 14(3):171–176PubMedCrossRef

15.

Johnston M (2005) Breast cancer drop linked to fall in use of HRT. New Zealand Herald December 20, 2006, Sect. Accessed electronically at http://www.nzherald.co.nz/section/1/story.cfm?c_id = 1&objectid = 10416198

16.

Centers for Disease Control (2007) Use of mammograms among women aged < or = 40 years—United States, 2000–2005. MMWR Morb Mortal Wkly Rep 56(3):49–51

17.

California Health Interview Survey (2007) CHIS public use files 2001, 2003, 2005. Available from www.chis.ucla.edu [Cited, accessed January, 2007]

18.

Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 9(3):R28PubMedCrossRef

19.

Centers for Disease Control (2006) Behavioral risk factor surveillance system

20.

Dietel M, Lewis MA, Shapiro S (2005) Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20(8):2052–2060PubMedCrossRef

21.

Key TJ, Pike MC (1988) The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24(1):29–43PubMedCrossRef

22.

Pike MC (2005) The role of mammographic density in evaluating changes in breast cancer risk. Gynecol Endocrinol 21(Suppl 1):1–5PubMedCrossRef

23.

Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382):419–427PubMedCrossRef

24.

Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918PubMedCrossRef

25.

Austin DF, Roe KM (1979) Increase in cancer of the corpus uteri in the San Francisco-Oakland standard metropolitan statistical area, 1960–75. J Natl Cancer Inst 62(1):13–16PubMed

26.

Weiss NS, Szekely DR, Austin DF (1976) Increasing incidence of endometrial cancer in the United States. N Engl J Med 294(23):1259–1262PubMedCrossRef

27.

Smith DC, Prentice R, Thompson DJ, Herrmann WL (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293(23):1164–1167PubMedCrossRef

28.

Austin DF, Roe KM (1982) The decreasing incidence of endometrial cancer: public health implications. Am J Public Health 72(1):65–68PubMedCrossRef

29.

Glass AG, Hoover RN (1990) Rising incidence of breast cancer: relationship to stage and receptor status. J Natl Cancer Inst 82(8):693–696PubMedCrossRef

30.

Clarke CA, Purdie DM, Glaser SL (2006) Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer 6:170PubMedCrossRef

31.

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. Jama 289(24):3243–3253PubMedCrossRef

32.

Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL et al (2006) Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trial of estrogen plus progestin. Maturitas 55(2):103–115PubMedCrossRef

33.

North American Association of Central Cancer Registries (2007) Cancer in North America (CINA + Online). Springfield, Illinois. http://www.naaccr.org/cinap/

34.

Coombs NJ, Taylor R, Wilcken N, Fiorica J, Boyages J (2005) Hormone replacement therapy and breast cancer risk in California. Breast J 11(6):410–415PubMedCrossRef

35.

Food and Drug Administration. Prempro (NDA 020527) label and approval history, revisions 8/2002,1/2003,8/2004,1/2007. www.accessdata.fda.gov, accessed 15 May 2007

Titel: Declines in breast cancer after the WHI: apparent impact of hormone therapy
verfasst von: Christina A. Clarke
Sally L. Glaser
Publikationsdatum: 01.10.2007
Verlag: Kluwer Academic Publishers
Erschienen in: Cancer Causes & Control / Ausgabe 8/2007
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-007-9029-1

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Declines in breast cancer after the WHI: apparent impact of hormone therapy

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2007

The effect of atopy, childhood crowding, and other immune-related factors on non-Hodgkin lymphoma risk

Lack of evidence for effect modification by estrogen of association between body mass index and colorectal cancer risk among postmenopausal women

Consumption of soy foods and the risk of breast cancer: findings from the Japan Collaborative Cohort (JACC) Study

Health behaviors of cancer survivors: data from an Australian population-based survey

Dietary carbohydrate, glycemic index, and glycemic load and the risk of colorectal cancer in the BCDDP cohort

Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie